Time to Prostate Specific Antigen Recurrence After Radical Prostatectomy and Risk of Prostate Cancer Specific Mortality
2006; Lippincott Williams & Wilkins; Volume: 176; Issue: 4 Linguagem: Inglês
10.1016/j.juro.2006.06.017
ISSN1527-3792
AutoresStephen J. Freedland, Elizabeth B. Humphreys, Leslie A. Mangold, Mario A. Eisenberger, Alan W. Partin,
Tópico(s)Hepatitis B Virus Studies
ResumoNo AccessJournal of UrologyAdult urology1 Oct 2006Time to Prostate Specific Antigen Recurrence After Radical Prostatectomy and Risk of Prostate Cancer Specific Mortality Stephen J. Freedland, Elizabeth B. Humphreys, Leslie A. Mangold, Mario Eisenberger, and Alan W. Partin Stephen J. FreedlandStephen J. Freedland , Elizabeth B. HumphreysElizabeth B. Humphreys , Leslie A. MangoldLeslie A. Mangold , Mario EisenbergerMario Eisenberger , and Alan W. PartinAlan W. Partin View All Author Informationhttps://doi.org/10.1016/j.juro.2006.06.017AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: In patients treated with radical prostatectomy who have biochemical recurrence we have previously reported that time from surgery to biochemical recurrence and postoperative prostate specific antigen doubling time are significantly related to the risk of prostate cancer death. We performed a more thorough examination of the association of time from surgery to biochemical recurrence and the risk of prostate cancer death. Materials and Methods: We retrospectively studied the records of 379 patients treated with radical prostatectomy between 1982 and 2000 who had had biochemical recurrence. We examined the association of time from surgery to prostate specific antigen recurrence and prostate specific antigen doubling time, and the risk of prostate cancer death using the Spearman correlation and Cox proportional hazards regression, respectively. Results: Longer time from surgery to prostate specific antigen recurrence was associated with a slower prostate specific antigen doubling time (Spearman r = 0.36, p <0.001) and a decreased risk of prostate cancer death (RR 0.76, 95% CI 0.66 to 0.88, p <0.001). The 15-year actuarial prostate cancer specific survival rate after biochemical recurrence in patients with recurrence at 3 years or less was 41% (95% CI 29 to 53) compared to 87% (95% CI 75 to 93) in patients with recurrence more than 3 years after radical prostatectomy. On multivariate analysis a shorter time from surgery to prostate specific antigen recurrence was associated with an increased risk of prostate cancer death (3 or less vs more than 3 years, RR 2.70, 95% CI 1.37 to 5.31, p = 0.004). Conclusions: Earlier prostate specific antigen recurrence is associated with an increased risk of prostate cancer death. These data suggest that perhaps time to prostate specific antigen recurrence may be a reasonable intermediate end point in patients treated with radical prostatectomy, although this must be validated in other studies. References 1 : Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology2003; 61: 365. Google Scholar 2 : Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol2001; 165: 1146. Link, Google Scholar 3 : Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst2003; 95: 1376. Google Scholar 4 : Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA2005; 294: 433. Google Scholar 5 : Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol2004; 171: 2221. Link, Google Scholar 6 : Natural history of progression after PSA elevation following radical prostatectomy. JAMA1999; 281: 1591. Crossref, Medline, Google Scholar 7 : Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol2004; 171: 2260. Link, Google Scholar 8 : The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol2003; 170: 1872. Link, Google Scholar 9 : Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol2001; 166: 2198. Link, Google Scholar 10 : Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA2004; 291: 1325. Google Scholar 11 : Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol2004; 171: 1141. Link, Google Scholar 12 : A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol2002; 42: 204. Google Scholar 13 : Early versus late hormonal therapy: debating the issues. Urology2003; 61: 8. Google Scholar 14 : Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med1999; 341: 1781. Crossref, Medline, Google Scholar Departments of Urology and Oncology, The James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, Maryland© 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byShee K, Washington S, Cowan J, de la Calle C, Baskin A, Chappidi M, Escobar D, Nguyen H, Cooperberg M and Carroll P (2022) Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional CohortJournal of Urology, VOL. 209, NO. 1, (198-207), Online publication date: 1-Jan-2023.Koulikov D, Mohler M, Mehedint D, Attwood K, Wilding G and Mohler J (2014) Low Detectable Prostate Specific Antigen after Radical Prostatectomy—Treat or Watch?Journal of Urology, VOL. 192, NO. 5, (1390-1396), Online publication date: 1-Nov-2014.Boorjian S, Tollefson M, Thompson R, Rangel L, Bergstralh E and Karnes R (2012) Natural History of Biochemical Recurrence After Radical Prostatectomy with Adjuvant Radiation TherapyJournal of Urology, VOL. 188, NO. 5, (1761-1766), Online publication date: 1-Nov-2012.Barocas D, Salem S, Kordan Y, Herrell S, Chang S, Clark P, Davis R, Baumgartner R, Phillips S, Cookson M and Smith J (2010) Robotic Assisted Laparoscopic Prostatectomy Versus Radical Retropubic Prostatectomy for Clinically Localized Prostate Cancer: Comparison of Short-Term Biochemical Recurrence-Free SurvivalJournal of Urology, VOL. 183, NO. 3, (990-996), Online publication date: 1-Mar-2010.Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou C and de la Taille A (2009) Pathological Findings and Prostate Specific Antigen Outcomes After Radical Prostatectomy in Men Eligible for Active Surveillance—Does the Risk of Misclassification Vary According to Biopsy Criteria?Journal of Urology, VOL. 183, NO. 2, (539-545), Online publication date: 1-Feb-2010.Bañez L, Sun L, Trock B, Han M, Partin A, Aronson W, Terris M, Presti J, Kane C, Amling C, Moul J and Freedland S (2009) Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After ProstatectomyJournal of Urology, VOL. 182, NO. 2, (491-498), Online publication date: 1-Aug-2009.Walz J, Chun F, Klein E, Reuther A, Saad F, Graefen M, Huland H and Karakiewicz P (2008) Nomogram Predicting the Probability of Early Recurrence After Radical Prostatectomy for Prostate CancerJournal of Urology, VOL. 181, NO. 2, (601-608), Online publication date: 1-Feb-2009.Teeter A, Bañez L, Presti J, Aronson W, Terris M, Kane C, Amling C and Freedland S (2008) What are the Factors Associated With Short Prostate Specific Antigen Doubling Time After Radical Prostatectomy? A Report From the SEARCH Database GroupJournal of Urology, VOL. 180, NO. 5, (1980-1985), Online publication date: 1-Nov-2008.Jayachandran J, Bañez L, Levy D, Aronson W, Terris M, Presti J, Amling C, Kane C and Freedland S (2008) Risk Stratification for Biochemical Recurrence in Men With Positive Surgical Margins or Extracapsular Disease After Radical Prostatectomy: Results From the SEARCH DatabaseJournal of Urology, VOL. 179, NO. 5, (1791-1796), Online publication date: 1-May-2008. Volume 176Issue 4October 2006Page: 1404-1408 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsprostatemortalityprostatectomyprostate-specific antigenprostatic neoplasmsMetricsAuthor Information Stephen J. Freedland More articles by this author Elizabeth B. Humphreys More articles by this author Leslie A. Mangold More articles by this author Mario Eisenberger More articles by this author Alan W. Partin More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)